Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1514-1521

  Cabanillas, Maria E ^a   Lu, Huifang ^a   Fang, Shenying ^b   Du, Xianglin L ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Fracture; Non Hodgkin's lymphoma; Osteoporosis

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NONHODGKIN LYMPHOMA; OSTEOPOROSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FRACTURES, BONE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; OSTEOPOROSIS; PROGNOSIS; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE;

EID: 34547966607     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701471973     Document Type: Article

References (45)

1. Holland, J. F., Frei III, E., Bast Jr, R., Kufe, D., Morton, D. and Weichselbaum, R. (1997) Cancer Medicine. Anticancer Drugs from Plants: Vinca Alkaloids and Taxanes, 1, p. 1011. Williams & Wilkins, Baltimore
2. DeMott, T. K., Richardson, J. K., Thies, S. B. and Ashton-Miler, J. A. (2007) Falls and gait characteristics among older persons with peripheral neuropathy. Am J Phys Med Rehabil, 86, pp. 125-132.
3. Koski, K., Luukinen, H., Laippala, P. and Kivelä, S. (1998) Risk factors for major injurious falls among the home-dwelling elderly by functional abilities. Gerontology, 44, pp. 232-238.
4. Richardson, J. K. and Hurvitz, E. A. (1995) Peripheral neuropathy: A true risk factor for falls. J Gerontol A Biol Sci Med Sci, 50, pp. M211-M215.
5. Ansell, S. M. and Armitage, J. (2005) Non-Hodgkin lymphoma: Diagnosis and treatment. Mayo Clin Proc, 80, pp. 1087-1097.
6. National Osteoporosis Foundation: Disease facts
7. Reginster, J. Y. and Burlet, N. (2006) Osteoporosis: A still increasing prevalence. Bone, 38:2, pp. S4-S9. S4-S9.
8. International Osteopososis Foundation: Epidemiology
9. Shapiro, C. L., Manola, J. and Leboff, M. (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol, 19, pp. 3306-3311.
10. Eastell, R., Hannon, R. A., Cuzick, J., Dowsett, M., Clack, G. and Adams, J. E. (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res, 21, pp. 1215-1223.
11. Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y. J. and Vincelette, A. (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab, 86, pp. 2787-2791.
12. Lopez, A. M., Pena, M. A., Hernandez, R., Val, F., Martin, B. and Riancho, J. A. (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int, 16, pp. 707-711.
13. Brown, J. E., Ellis, S. P., Silcocks, P., Blumsohn, A., Gutcher, S. A. and Radstone, C. (2006) Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res, 12, pp. 6480-6486.
14. Holmes, S. J., Whitehouse, R. W., Clark, S. T., Crowther, D. C., Adams, J. E. and Shalet, S. M. (1994) Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer, 70, pp. 371-375.
15. Redman, J. R., Bajorunas, D. R., Wong, G., McDermott, K., Gnecco, C. and Schneider, R. (1988) Bone mineralization in women following successful treatment of Hodgkin's disease. Am J Med, 85, pp. 65-72.
16. Potosky, A. L., Riley, G. F., Lubitz, J. D., Mentnech, R. M. and Kessler, L. G. (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care, 31, pp. 732-748.
17. Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B. and Riley, G. F. (2002) Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care, 40, pp. 3-18.
18. Warren, J. L., Harlan, L. C., Fahey, A., Virnig, B. A., Freeman, J. L. and Klabunde, C. N. (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care, 40, pp. 55-61.
19. Ries, L AG, Harkins, D., Krapcho, M., Marriotto, A., Miller, B. A. and Feuer, E. J. (2006) SEER Cancer Statistics Review, 1975-2003, National Cancer Institute, Bethesda, MD
20. Zippin, C., Lum, D. and Hankey, B. F. (1995) Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer, 76, pp. 2343-2350.
21. Goodwin, J. S. (2001) Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol, 19, pp. 1455-1461.
22. Du, X. L., Key, C. R., Dickie, L., Darling, R., Geraci, J. M. and Zhang, D. (2006) External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care, 44, pp. 124-131.
23. US Public Health Services (1996) International Classification of Diseases, 9th revision, Clinical Modification, Practice Management Information Corporation, Los Angeles
24. American Medical Association (1993) Physicians' current procedural terminology-CPT 94, American Medical Association, Chicago
25. Health Care Financing Administration (1994) HCFA common procedure coding system (HCPCS): National level II Medicare codes, Practice Management Information Corporation, Los Angeles
26. Health Care Financing Administration (1999) HCFA Data Dictionary: Revenue Center Codes, Health Care Financing Administration, Baltimore, MD
27. Freeman, J. L. and Goodwin, J. S. (1999) Information on radiation treatment in patients with breast cancer: The advantages of the linked medicare and SEER data. Surveillance epidemiology and end results. J Clin Epidemiol, 52, pp. 463-470.
28. Virnig, B. A., Warren, J. L., Cooper, G. S., Klabunde, C. N., Schussler, N. and Freeman, J. (2002) Studying radiation therapy using SEER-Medicare-linked data. Med Care, 40, pp. 49-54.
29. Du, X. L., Chan, W., Giordano, S., Geraci, J. M., Delclos, G. L. and Burau, K. (2005) Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer, 104, pp. 913-924.
30. Klabunde, C. N., Potosky, A. L., Legler, J. M. and Warren, J. L. (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol, 53, pp. 1258-1267.
31. Stokes, M., Davis, C. and Koch, G. (1997) Categoricia data analysis using the SAS system, SAS Institute, Cary, NC
32. Vermeulen, A. (2000) Andropause. Maturitas, 34, pp. 5-15.
33. Marystone, J. F., Barrett-Connor, E. L. and Morton, D. J. (1995) Inhaled and oral corticosteroids: Their effects on bone mineral density in older adults. Am J Public Health, 85, pp. 1693-1695.
34. van Staa, T. P. (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int, 79, pp. 129-137.
35. Kamischke, A., Kemper, D. E., Castel, M. A., Luthke, M., Rolf, C. and Behre, H. M. (1998) Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J, 11, pp. 41-45.
36. MacAdams, M. R., White, R. H. and Chipps, B. E. (1986) Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med, 104, pp. 648-651.
37. Szulc, P., Claustrat, B., Marchand, F. and Delmas, P. D. (2003) Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: The MINOS study. J Clin Endocrinol Metab, 88, pp. 5240-5247.
38. Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J. and Choi, Y. (2006) Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol, 24, pp. 33-63.
39. Cooper, C. (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med, 103, pp. 12S-17S.
40. Silverman, S. L. (2005) Quality-of-life issues in osteoporosis. Curr Rheumatol Rep, 7, pp. 39-45.
41. Cummings, S. R. and Melton, L. J. (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet, 359, pp. 1761-1767.
42. Deramond, H., Saliou, G., Aveillan, M., Lehmann, P. and Vallee, J. N. (2006) Respective contributions of vertebroplasty and kyphoplasty to the management of osteoporotic vertebral fractures. Joint Bone Spine, 73, pp. 610-613.
43. Gehlbach, S BC, Heimisdottir, M., May, S., Walker, M. and Kirkwood, J. (2000) Recognition of vertebral fracture in a clinical setting. Osteoporos Int, 11, pp. 577-582.
44. Hainsworth, J. D., Litchy, S., Burris III, H. A., Scullin Jr, D. C., Corso, S. W. and Yardley, D. A. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol, 20, pp. 4261-4267.
45. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P. and Delwail, V. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood, 97, pp. 101-106.